Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation

Christine Årdal¹, Enrico Baraldi², Reinhard Busse³, Rosa Castro⁴, Francesco Ciabuschi⁵, José Miguel Cisneros⁶, Inge C Gyssens⁷, Stephan Harbarth⁸, Tomislav Kostyanev⁹, Yohann Lacotte¹⁰, Nicola Magrini¹¹, Anthony McDonnell¹², Annelie A Monnier¹³, Suerie Moon¹⁴, Elias Mossialos¹⁵, Germán Peñalva¹⁶, Marie-Cécile Ploy¹⁰, Momir Radulović¹⁷, Adrián Alonso Ruiz¹⁴, John-Arne Røttingen¹⁸, Michael Sharland¹⁹, Evelina Tacconelli²⁰, Ursula Theuretzbacher²¹, Sabine Vogler²², Ute Wolff Sönksen²³, Kerstin Åkerfeldt²⁴, Otto Cars²⁴, Jim O'Neill²⁵

Affiliations

¹ Antimicrobial Resistance Centre, Norwegian Institute of Public Health, Oslo 0213, Norway. Electronic address: chaa@fhi.no.
² Department of Engineering Sciences, Industrial Engineering and Management, Uppsala University, Uppsala, Sweden.
³ Department of Health Care Management, Berlin University of Technology, Berlin, Germany.
⁴ European Public Health Alliance, Brussels, Belgium.
⁵ Department of Business Studies, Uppsala University, Uppsala, Sweden.
⁶ Department of Infectious Diseases, University Hospital Virgen del Rocio, IBiS, CIBERINFEC, Seville, Spain.
⁷ Department of Internal Medicine, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
⁸ Hôpitaux Universitaires de Genève, Geneva, Switzerland.
⁹ Laboratoire National de Santé, Dudelange, Luxembourg.
¹⁰ University of Limoges, INSERM, CHU Limoges, RESINFIT, Limoges, France.
¹¹ AIFA-Italian Medicines Agency, Rome, Italy.
¹² Center for Global Development, London, UK.
¹³ Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
¹⁴ Graduate Institute of International and Development Studies, Geneva, Switzerland.
¹⁵ London School of Economics and Political Science, London, UK.
¹⁶ Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospital Virgen del Rocio, Seville, Spain.
¹⁷ Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, Ljubljana, Slovenia.
¹⁸ Norwegian Ministry of Foreign Affairs, Oslo, Norway.
¹⁹ Centre for Neonatal and Paediatric Infection, St George's University of London, London, UK.
²⁰ University of Verona, Verona, Italy.
²¹ Center for Anti-Infective Agents, Vienna, Austria.
²² Austrian National Public Health Institute, Vienna, Austria; Department of Health Care Management, Berlin University of Technology, Berlin, Germany.
²³ Statens Serum Institut, Copenhagen, Denmark.
²⁴ ReAct Europe, Uppsala University, Uppsala, Sweden.
²⁵ The Review on Antimicrobial Resistance, London, UK.

PMID: 36774936
DOI: 10.1016/S0140-6736(23)00282-9

Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation

Christine Årdal et al. Lancet. 2024.

. 2024 Jan 13;403(10422):e2-e4.

doi: 10.1016/S0140-6736(23)00282-9. Epub 2023 Feb 9.

Authors

Affiliations

¹ Antimicrobial Resistance Centre, Norwegian Institute of Public Health, Oslo 0213, Norway. Electronic address: chaa@fhi.no.
² Department of Engineering Sciences, Industrial Engineering and Management, Uppsala University, Uppsala, Sweden.
³ Department of Health Care Management, Berlin University of Technology, Berlin, Germany.
⁴ European Public Health Alliance, Brussels, Belgium.
⁵ Department of Business Studies, Uppsala University, Uppsala, Sweden.
⁶ Department of Infectious Diseases, University Hospital Virgen del Rocio, IBiS, CIBERINFEC, Seville, Spain.
⁷ Department of Internal Medicine, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
⁸ Hôpitaux Universitaires de Genève, Geneva, Switzerland.
⁹ Laboratoire National de Santé, Dudelange, Luxembourg.
¹⁰ University of Limoges, INSERM, CHU Limoges, RESINFIT, Limoges, France.
¹¹ AIFA-Italian Medicines Agency, Rome, Italy.
¹² Center for Global Development, London, UK.
¹³ Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
¹⁴ Graduate Institute of International and Development Studies, Geneva, Switzerland.
¹⁵ London School of Economics and Political Science, London, UK.
¹⁶ Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospital Virgen del Rocio, Seville, Spain.
¹⁷ Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, Ljubljana, Slovenia.
¹⁸ Norwegian Ministry of Foreign Affairs, Oslo, Norway.
¹⁹ Centre for Neonatal and Paediatric Infection, St George's University of London, London, UK.
²⁰ University of Verona, Verona, Italy.
²¹ Center for Anti-Infective Agents, Vienna, Austria.
²² Austrian National Public Health Institute, Vienna, Austria; Department of Health Care Management, Berlin University of Technology, Berlin, Germany.
²³ Statens Serum Institut, Copenhagen, Denmark.
²⁴ ReAct Europe, Uppsala University, Uppsala, Sweden.
²⁵ The Review on Antimicrobial Resistance, London, UK.

PMID: 36774936
DOI: 10.1016/S0140-6736(23)00282-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

RB has received personal honoraria from AbbVie and Eli Lilly unrelated to the topic of this Comment. All other authors declare no competing interests.

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation

Affiliations

Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation

Authors

Affiliations

Conflict of interest statement

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical